Beauty heroes: Dr Barbara Sturm
Sturm began her career as an orthopaedics specialist, studying at Heinrich Heine University in Düsseldorf where she learnt about treatments to alleviate the inflammation caused by osteoarthritis. Together with her team she focused on finding ways to use the body's own proteins and healing factors to lower inflammation markers and tackle joint pain. This research led Sturm to consider how some of the techniques she'd been studying might be beneficial in the aesthetics world. She also concluded that inflammation was the biggest enemy of an anti-ageing routine.
By 2014 Sturm had launched a full skincare line and in the years that followed she opened spas in London, New York, Miami and LA, which feature the brand's 300 products, all of which are available over the counter and formulated in such a way that each customer can find the right combination for their skin's needs.
Sturm's line has a focus on 'molecular repair', which means that the products are designed to work on a cellular level to heal and repair the skin. The one she is possibly the most passionate about is her Hyaluronic Serum formulation. 'It is basically the 'white T-shirt' of your skincare routine. This is because it's the product you use every morning and every night, like your basics,' Sturm explained. 'We make [our Hyaluronic Serum] with the highest possible integrity, quality and efficacy.'
Watch how Sturm and her team make her hero Hyaluronic Serum at their laboratory. Direction: Mona TehraniDOP: Camille GuillemainEdit: Laurène VanackerProduction: Sarah Barnes
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
25 minutes ago
- Reuters
Well-heeled shoppers shrug off price hikes for Birkenstocks and Bugaboo strollers for now
LONDON, Aug 14 (Reuters) - Well-heeled shoppers around the United States seem - so far at least - willing to soak up price hikes for aspirational products from trendy Birkenstock sandals to Bugaboo prams, despite the impact of trade tariffs and belt-tightening elsewhere. German sandal and clog brand Birkenstock (BIRK.N), opens new tab has enjoyed strong consumer demand with little pushback from U.S. retailers since hiking prices at the start of July, its chief executive said on Thursday. As brands raise prices and cut costs to mitigate the impact of higher U.S. tariffs on their imported products, a key question is the extent to which consumers will be put off and buy less, or simply walk away from purchases. Comments from Birkenstock, Bugaboo, Coach, Ralph Lauren and other brands at the premium end of the market suggest that, so far, affluent consumers are shrugging off price hikes. "We saw no pushback or cancellations following the July 1st price increases implemented in response to tariffs," Birkenstock CEO Oliver Reichert told analysts on a call, adding demand for the brand has been "tremendously strong." Bank of America, the largest consumer facing U.S. bank, said this week that middle- and upper-income earners spent more on their credit cards in July than the same month last year. In contrast, spending among the lowest income bracket remained flat, the bank found. Overall U.S. consumer spending may stay strong, Bank of America said, as long as higher-income individuals keep spending. Lower-income earners account for only 15% of all U.S. consumer spending, according to Bank of America. However, Procter & Gamble (PG.N), opens new tab, maker of Tide detergent, reported signs of spending cutbacks among higher-income consumers, indicating that shoppers may be becoming more selective with their purchases. Bugaboo, a Netherlands-based maker of expensive baby gear, also raised prices on its strollers, high chairs and play pens by $50-$300 in May because of U.S. tariffs. Retailers were open and accepting. "In general we did not see any pushback. They are like us. They understand it is a fluid situation," Chief Commercial Officer for North America, Jeanelle Teves, said. Bugaboo manufactures in China and sells strollers for more than $1,000 at Target, Nordstrom, Bloomingdales and independent mom and pop stores. Coach handbags also remain in strong demand despite a gloomier economic outlook: the brand drew in more than 4.6 million new customers in North America this year, many of whom are Gen Z and millennials, Tapestry CEO Joanne Kuvoiserat said on Thursday. Coach, whose popular Tabby shoulder bags retail for $350, will maintain its operating profit margin despite the pressure of tariffs, Kuvoiserat said. Ralph Lauren, meanwhile, raised its annual revenue forecast as shoppers snapped up items like its $398 Polo Bear sweaters. But consumers' behavior in the coming months remains hard to predict, CEO Patrice Louvet highlighted on a conference call with analysts. "The bigger unknown here today is the price sensitivity and how the consumer reacts to the broader pricing environment. So that's what we're watching very closely as we head into the second half."
Times
an hour ago
- Times
Diploma finance chief quits over ‘comments to female colleague'
The £1.5 million-a-year chief financial officer of a FTSE 100 company has left with immediate effect after allegedly making inappropriate comments to a female colleague. Diploma, a £7 billion industrial group, announced on Thursday that Chris Davies, its finance chief, 'has resigned from his role and will step down from the board with immediate effect'. It added: 'This decision follows a recent company event where, through a lapse in judgment, his personal behaviour did not meet the high standards required of the group's leadership team.' Diploma is an industrial equipment distribution business The company declined to say anything more. Industry sources claimed that Davies was asked to resign following reports to executives regarding comments made at the event towards a female colleague. Davies will leave with no compensation. Executives can typically expect to receive a year's money when they resign, but the company confirmed: 'No payments will be made for loss of office.' Davies, 55, was on a basic salary of £510,000 a year and bonuses last year increased that to a total of £1.53 million. That reflects the strong performance of Diploma in recent times. The supplier of industrial components, cabling, seals, hoses and fasteners has been one of the great successes of the stock market in recent years and especially so under its current £4.5 million-a-year chief executive Johnny Thomson, who joined the company six years ago. Diploma's share price has risen from £5 in 2015 to the current £52.90. Following the news of Davies's departure, the shares were down 155p, or 2.9 per cent, from the £54.45 all-time high they had closed at on Wednesday evening. Davies joined Diploma in late 2022 after a five-year stint as finance director at National Express, the coach and bus group. Before that he had been group financial controller at Inchcape, the car dealer, and held senior roles at the drinks giant Diageo. Diploma has appointed Wilson Ng, 43, as its acting chief financial officer while it begins the process of finding a replacement for Davies. Ng joined Diploma in 2022, having previously been a divisional finance director at Spirax, the FTSE 100 engineer.
Times
an hour ago
- Times
Junior doctors strikes: NHS staff absence due to walkouts falls
NHS staff absences due to industrial action fell by 7.5 per cent compared with the last round of junior doctors' strikes, with 1,243 fewer staff absent during the most recent walkout. The analysis from the health service also found that more care was delivered during the five-day strike than in previous industrial action. Junior doctors, now known as resident doctors in the NHS, walked out for five days on July 25 in a dispute with the government over pay. Wes Streeting, the health secretary, and the British Medical Association (BMA) say they are continuing talks over the summer to prevent further strike action from the doctors. The NHS estimated that 11,071 more appointments and procedures went ahead as planned compared with industrial action from junior doctors in 2024. In previous industrial action, hospitals cancelled or rescheduled elective procedures to prepare for the walkouts. However, during this round of strikes, hospitals endeavoured to keep planned appointments going ahead as scheduled throughout the walk-outs. Streeting said the figures show the NHS 'was more resilient against last month's strike action than ever before'. 'We are getting on with the job of delivering progress in the face of strike action, and we will continue to put patients first,' he said. 'I had a constructive conversation with the BMA last week and I am glad they've agreed to continue engagement through the summer with the mutual aim of preventing further disruption to the NHS and patients.' Professor Meghana Pandit, NHS national medical director, said: 'It is very welcome news that the resident doctors committee has returned to talks, and we hope this leads to a resolution that avoids further disruption for patients.' Daniel Elkeles, chief executive of NHS Providers, which represents hospital trusts, said: 'Despite a five-day strike in July by some doctors, the NHS provided an estimated 11,000 more appointments and procedures compared to during their five-day walkout in July last year.' • NHS patients told to brace for strikes until Christmas and beyond 'We hope that talks between the union and the government bear fruit and that any more disruptive strikes can be avoided. NHS trust leaders want to focus on improving services for patients and doing everything they can to improve things for valued resident doctors.' The doctors' union has, however, said that the action 'was totally avoidable'. It has previously said that the difference in absences could not be accurately compared between the strike years due to changes in the numbers taking annual leave. A spokesman added: 'Had the government just come forward with a credible offer toward pay restoration for resident doctors, those doctors would have been at work. Instead, government inaction meant we saw yet more cancellations, delays and chaos in a health system that is already seeing far too much of all three. 'We hope government uses the opportunity of our ongoing talks to avoid any need for future action. Today's figures show there are far too many patients on waiting lists relying on a swift and just resolution to this dispute.' Separate NHS figures show that the health service delivered a record number of appointments in June, with 103,563 more treatments carried out than this time last year. The latest performance data from NHS England shows an estimated 7.37 million treatments were waiting to be carried out at the end of June, relating to 6.23 million patients — up from 7.36 million treatments and just under 6.23 million patients at the end of May. The slight increase, which NHS officials have put down to more people coming forward for appointments, comes after the list fell for two consecutive months. The numbers waiting for more than 18 months to start treatment were also down to 1,103, from 1,237 in May. Some 10,517 patients had been waiting more than 65 weeks, down from 11,522 the previous month. This figure stood at 58,024 in June 2024. The number of patients waiting more than 52 weeks to start routine treatment also fell to 191,813 from 196,920 at the end of May. Tim Gardner, assistant director of policy at the Health Foundation, said: 'While summer is often a time for the NHS to catch its breath, today's data shows hospitals and ambulance services remain under relentless pressure.'
